VistaGen Therapeutics, Inc.
VTGN
$1.97
-$0.08-3.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -107.61% | -43.07% | -34.17% | -52.54% | 12.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -107.61% | -43.07% | -34.17% | -52.54% | 12.00% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -107.61% | -43.07% | -34.17% | -52.54% | 12.00% |
| SG&A Expenses | 3.71% | 7.74% | 30.81% | 53.36% | 33.86% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.30% | 85.10% | 104.17% | 70.24% | -6.92% |
| Operating Income | -27.61% | -91.78% | -109.84% | -73.35% | 7.19% |
| Income Before Tax | -43.22% | -121.87% | -96.63% | -55.55% | 22.14% |
| Income Tax Expenses | -100.00% | -- | -- | -- | 100.00% |
| Earnings from Continuing Operations | -43.21% | -121.87% | -96.74% | -55.48% | 22.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.21% | -121.87% | -96.74% | -55.48% | 22.13% |
| EBIT | -27.61% | -91.78% | -109.84% | -73.35% | 7.19% |
| EBITDA | -27.63% | -92.04% | -110.25% | -73.66% | 7.20% |
| EPS Basic | -38.46% | -112.26% | 35.50% | 62.72% | 81.73% |
| Normalized Basic EPS | -38.53% | -112.37% | 35.54% | 62.71% | 81.74% |
| EPS Diluted | -38.46% | -112.26% | 35.50% | 62.72% | 81.73% |
| Normalized Diluted EPS | -38.53% | -112.37% | 35.54% | 62.71% | 81.74% |
| Average Basic Shares Outstanding | 3.41% | 4.50% | 205.03% | 317.11% | 326.26% |
| Average Diluted Shares Outstanding | 3.41% | 4.50% | 205.03% | 317.11% | 326.26% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |